These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25505249)

  • 21. [Optimization of the use of phosphodiesterase-5 inhibitors].
    Pushkar' DIu; Segal AS
    Urologiia; 2012; (4):79-80, 82. PubMed ID: 23116030
    [No Abstract]   [Full Text] [Related]  

  • 22. PDE5 modulates oocyte spontaneous maturation via cGMP-cAMP but not cGMP-PKG signaling.
    Wang S; Ning G; Chen X; Yang J; Ouyang H; Zhang H; Tai P; Mu X; Zhou B; Zhang M; Xia G
    Front Biosci; 2008 May; 13():7087-95. PubMed ID: 18508718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PDE5 inhibitors: targeting erectile dysfunction in diabetics.
    Francis SH; Corbin JD
    Curr Opin Pharmacol; 2011 Dec; 11(6):683-8. PubMed ID: 21924956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
    Sawant SD; Lakshma Reddy G; Dar MI; Srinivas M; Gupta G; Sahu PK; Mahajan P; Nargotra A; Singh S; Sharma SC; Tikoo M; Singh G; Vishwakarma RA; Syed SH
    Bioorg Med Chem; 2015 May; 23(9):2121-8. PubMed ID: 25801159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway.
    Andric SA; Janjic MM; Stojkov NJ; Kostic TS
    Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E544-50. PubMed ID: 20663985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass.
    Kim SM; Taneja C; Perez-Pena H; Ryu V; Gumerova A; Li W; Ahmad N; Zhu LL; Liu P; Mathew M; Korkmaz F; Gera S; Sant D; Hadelia E; Ievleva K; Kuo TC; Miyashita H; Liu L; Tourkova I; Stanley S; Lizneva D; Iqbal J; Sun L; Tamler R; Blair HC; New MI; Haider S; Yuen T; Zaidi M
    Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14386-14394. PubMed ID: 32513693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle.
    Murthy KS
    Biochem J; 2001 Nov; 360(Pt 1):199-208. PubMed ID: 11696008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
    Manganiello V
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
    [No Abstract]   [Full Text] [Related]  

  • 29. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
    Katsarov M
    Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
    [No Abstract]   [Full Text] [Related]  

  • 30. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
    Corbin JD
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
    Eardley I
    Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
    [No Abstract]   [Full Text] [Related]  

  • 32. The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer.
    Peak TC; Richman A; Gur S; Yafi FA; Hellstrom WJ
    Sex Med Rev; 2016 Jan; 4(1):74-84. PubMed ID: 27872007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Essential role of the cGMP/PKG signaling pathway in regulating the proliferation and survival of human renal carcinoma cells.
    Ren Y; Zheng J; Yao X; Weng G; Wu L
    Int J Mol Med; 2014 Nov; 34(5):1430-8. PubMed ID: 25244411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
    Mulhall JP; Montorsi F
    Eur Urol; 2006 Jan; 49(1):30-7. PubMed ID: 16263207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorometric detection of protein-ligand engagement: The case of phosphodiesterase5.
    Di Rocco G; Martinelli I; Pacifico S; Guerrini R; Cichero E; Fossa P; Franchini S; Cardarelli S; Giorgi M; Sola M; Ponterini G
    J Pharm Biomed Anal; 2018 Feb; 149():335-342. PubMed ID: 29132113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphodiesterase type 5 regulation in the penile corpora cavernosa.
    Lin CS
    J Sex Med; 2009 Mar; 6 Suppl 3():203-9. PubMed ID: 19267844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tadalafil (Cialis) once a day for erectile dysfunction.
    Med Lett Drugs Ther; 2008 Apr; 50(1283):27-8. PubMed ID: 18391900
    [No Abstract]   [Full Text] [Related]  

  • 39. Expression of messenger ribonucleic acid encoding for phosphodiesterase isoenzymes in human female genital tissues.
    Uckert S; Ellinghaus P; Albrecht K; Jonas U; Oelke M
    J Sex Med; 2007 Nov; 4(6):1604-9. PubMed ID: 17888073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
    Huang YY; Li Z; Cai YH; Feng LJ; Wu Y; Li X; Luo HB
    J Chem Inf Model; 2013 Nov; 53(11):3044-53. PubMed ID: 24180640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.